[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
May 3, 2000

Raloxifene and Risk of Vertebral Fracture in Postmenopausal Women

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor

JAMA. 2000;283(17):2236-2237. doi:10.1001/jama.283.17.2235

To the Editor: Dr Ettinger and colleagues1 reported that raloxifene reduced the risk of vertebral fractures in postmenopausal women with osteoporosis. However, their study appears to have several methodological difficulties. First, it is not clear how well concealment of allocation was guaranteed. For instance, while 23% of the patients stopped taking the study medication, information on the reason for withdrawal was provided for only 10% who dropped out because of adverse effects. Furthermore, the data were not analyzed on an "intent-to-treat" basis; 11% of the subjects were excluded from the analysis for unstated reasons. Inclusion of their data may have changed the results.

First Page Preview View Large
First page PDF preview
First page PDF preview
×